Organicell Regenerative Medicine Inc
For the period ended Oct 31, 2023. Filed Jan 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Jan 29, 2024
ZEOXStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| PAGE NO. | |
| Organicell Regenerative Medicine, Inc. | |
|---|---|
| Reports of Independent Registered Public Accounting Firms | F-2 |
| Consolidated Balance Sheets as of October 31, 2023 and 2022 | F-5 |
| Consolidated Statements of Operations for the Years Ended October 31, 2023 and 2022 | F-6 |
| Consolidated Statement of Changes In Stockholders’ Equity (Deficit) for the Years Ended October 31, 2023 and 2022 | F-7 |
| Consolidated Statements of Cash flows for the Years Ended October 31, 2023 and 2022 | F-8 |
| Notes to Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.